Dexamethasone-sparing Regimen is an Effective and Safe Alternative in Overall Antiemetic Protection: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2019 Oct 3

PMID 31574883

Citations 3

Authors

Yan-Lin Gu

Jia-Ming Xie

Jie Ren

Hua Cao

Jin-Rong Wei

Chao Chen

Le-Ning Shao

Guo-Qin Jiang

Affiliations

Soon will be listed here.

Abstract

Objective: We performed a meta-analyisis to evaluate the efficacy of maintenance dexamethasone against acute or delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetic risk chemotherapy regimen.

Methods: PubMed, Embase, and Cochrane Library were searched for eligible studies. Data comparing maintenance dexamethasone with single-dose dexamethasone during the acute, delayed, and overall phase of CINV were extracted. Overall risk ratio (RR) was used to estimate the efficacy and adverse effects.

Results: Nine studies were included. In delayed phase, maintenance dexamethasone has similar efficacy to single-dose dexamethasone for no emetic episodes (RR, 1.06; 95% confidence interval [CI], 1.00-1.14), complete response (RR, 1.04; 95% CI, 0.98-1.11), complete control (RR, 1.07; 95% CI, 0.98-1.16), and total control (RR, 1.06; 95% CI, 0.91-1.23). In overall phase, maintenance dexamethasone has similar efficacy to single-dose dexamethasone for no emetic episodes (RR, 1.02; 95% CI, 0.94-1.11), complete response (RR, 1.02; 95% CI, 0.95 -1.09), complete control (RR, 1.03; 95% CI, 0.94-1.13), total control (RR, 1.05; 95% CI, 0.90-1.23), and no rescue medication (RR, 1.07; 95% CI, 0.97-1.19). Maintenance dexamethasone was only superior to single-dose dexamethasone for no rescue medication during delayed phase (RR, 1.10; 95% CI, 1.01-1.21, P = .034). The incidence of hiccup was observed higher in maintenance dexamethasone group (RR = 3.16, 95% CI, 1.12-8.92).

Conclusion: The single-dose dexamethasone regimen offers high and similar overall control of symptoms as the maintenance dexamethasone regimen in this population. Multiple-day dexamethasone was suitable for patients who used rescue medication during the delayed phase.

Citing Articles

Molecular Engineering of Peptide-Drug Conjugates for Therapeutics.

Fang Y, Wang H Pharmaceutics. 2022; 14(1).

PMID: 35057106 PMC: 8779610. DOI: 10.3390/pharmaceutics14010212.

Dexamethasone Sensitizes Cancer Stem Cells to Gemcitabine and 5-Fluorouracil by Increasing Reactive Oxygen Species Production through NRF2 Reduction.

Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S Life (Basel). 2021; 11(9).

PMID: 34575034 PMC: 8470402. DOI: 10.3390/life11090885.

Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada.

Grant R, Rotstein C, Liu G, Forbes L, Vu K, Lee R Support Care Cancer. 2020; 28(10):5031-5036.

PMID: 32601854 PMC: 7324309. DOI: 10.1007/s00520-020-05588-6.

References

Hesketh P, Aapro M, Street J, Carides A . Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2009; 18(9):1171-7. DOI: 10.1007/s00520-009-0737-9. View

Aapro M, Fabi A, Nole F, Medici M, Steger G, Bachmann C . Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic.... Ann Oncol. 2010; 21(5):1083-8. DOI: 10.1093/annonc/mdp584. View

Hesketh P, Grunberg S, Gralla R, Warr D, Roila F, de Wit R . The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052.... J Clin Oncol. 2003; 21(22):4112-9. DOI: 10.1200/JCO.2003.01.095. View

Warr D, Hesketh P, Gralla R, Muss H, Herrstedt J, Eisenberg P . Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23(12):2822-30. DOI: 10.1200/JCO.2005.09.050. View

Hickok J, Roscoe J, Morrow G, Stern R, Yang B, Flynn P . Use of 5-HT3 receptor antagonists to prevent nausea and emesis caused by chemotherapy for patients with breast carcinoma in community practice settings. Cancer. 1999; 86(1):64-71. DOI: 10.1002/(sici)1097-0142(19990701)86:1<64::aid-cncr11>3.0.co;2-#. View

Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H . Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015; 20(5):855-65. DOI: 10.1007/s10147-015-0786-7. View

Kuritz S, Landis J, Koch G . A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health. 1988; 9:123-60. DOI: 10.1146/annurev.pu.09.050188.001011. View

Matsuura M, Satohisa S, Teramoto M, Tanaka R, Iwasaki M, Nishikawa A . Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase-II trial. J Obstet Gynaecol Res. 2015; 41(10):1607-13. DOI: 10.1111/jog.12748. View

Navari R, Aapro M . Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 374(14):1356-67. DOI: 10.1056/NEJMra1515442. View

10.

Bradburn M, Deeks J, Berlin J, Russell Localio A . Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med. 2006; 26(1):53-77. DOI: 10.1002/sim.2528. View

11.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E . 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119-v133. DOI: 10.1093/annonc/mdw270. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Lau J, Ioannidis J, Schmid C . Quantitative synthesis in systematic reviews. Ann Intern Med. 1998; 127(9):820-6. DOI: 10.7326/0003-4819-127-9-199711010-00008. View

14.

Sharma R, Tobin P, Clarke S . Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol. 2005; 6(2):93-102. DOI: 10.1016/S1470-2045(05)01735-3. View

15.

Koo W, Ang P . Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol. 1996; 7(1):71-4. DOI: 10.1093/oxfordjournals.annonc.a010483. View

16.

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. DOI: 10.1200/JCO.2017.74.4789. View

17.

Einhorn L, Rapoport B, Navari R, Herrstedt J, Brames M . 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer. 2016; 25(1):303-308. DOI: 10.1007/s00520-016-3449-y. View

18.

Inoue A, Yamada Y, Matsumura Y, Shimada Y, Muro K, Gotoh M . Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer. 2003; 11(8):528-32. DOI: 10.1007/s00520-003-0488-y. View

19.

Celio L, Denaro A, Agustoni F, Bajetta E . Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. J Support Oncol. 2011; 10(2):65-71. DOI: 10.1016/j.suponc.2011.06.007. View

20.

Vardy J, Chiew K, Galica J, Pond G, Tannock I . Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006; 94(7):1011-5. PMC: 2361221. DOI: 10.1038/sj.bjc.6603048. View